{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:51:17Z","timestamp":1793213477911,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["DK106341"],"award-info":[{"award-number":["DK106341"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["DK122194"],"award-info":[{"award-number":["DK122194"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","award":["DK078244"],"award-info":[{"award-number":["DK078244"]}],"id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","award":["DK082753"],"award-info":[{"award-number":["DK082753"]}],"id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jaut.2022.102883","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T07:53:07Z","timestamp":1660722787000},"page":"102883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Phosphatase control of cytokine-mediated overproduction of galactose-deficient IgA1, the main autoantigen in IgA nephropathy"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4033-1360","authenticated-orcid":false,"given":"Colin","family":"Reily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana V.","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2022.102883_bib1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2018111156","article-title":"Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1","volume":"30","author":"Rizk","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2022.102883_bib2","first-page":"251","article-title":"Double immunofluorescence studies of immunoglobulins, complement components and their control proteins in patients with IgA nephropathy","volume":"32","author":"Tomino","year":"1982","journal-title":"Acta Pathol. Jpn."},{"key":"10.1016\/j.jaut.2022.102883_bib3","first-page":"694","article-title":"[Intercapillary deposits of IgA-IgG]","volume":"74","author":"Berger","year":"1968","journal-title":"J. Urol. Nephrol."},{"key":"10.1016\/j.jaut.2022.102883_bib4","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2022.102883_bib5","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1523-1755.2001.0590031077.x","article-title":"Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy","volume":"59","author":"Hiki","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2022.102883_bib6","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1523-1755.2001.060003969.x","article-title":"Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients","volume":"60","author":"Allen","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2022.102883_bib7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels","volume":"71","author":"Moldoveanu","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2022.102883_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00281-012-0306-z","article-title":"Glycosylation of IgA1 and pathogenesis of IgA nephropathy","volume":"34","author":"Novak","year":"2012","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jaut.2022.102883_bib9","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2022.102883_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI5535","article-title":"Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies","volume":"104","author":"Tomana","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2022.102883_bib11","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1093\/ndt\/gfr448","article-title":"IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells","volume":"26","author":"Novak","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jaut.2022.102883_bib12","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1074\/mcp.M110.001834","article-title":"Clustered O-glycans of IgA1: defining macro- and microheterogeneity by use of electron capture\/transfer dissociation","volume":"9","author":"Takahashi","year":"2010","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jaut.2022.102883_bib13","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1074\/jbc.M211097200","article-title":"Initiation of O-glycan synthesis in IgA1 hinge region is determined by a single enzyme, UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2","volume":"278","author":"Iwasaki","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2022.102883_bib14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41581-019-0129-4","article-title":"Glycosylation in health and disease","volume":"15","author":"Reily","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jaut.2022.102883_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1074\/jbc.M109060200","article-title":"Cloning and expression of human core 1 beta1,3-galactosyltransferase","volume":"277","author":"Ju","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2022.102883_bib16","first-page":"629","article-title":"IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1","volume":"118","author":"Suzuki","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2022.102883_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006609","article-title":"GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway","volume":"13","author":"Kiryluk","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.jaut.2022.102883_bib18","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.2016091043","article-title":"Galactosylation of IgA1 is associated with common variation in C1GALT1","volume":"28","author":"Gale","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2022.102883_bib19","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1074\/jbc.M113.512277","article-title":"Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes","volume":"289","author":"Suzuki","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2022.102883_bib20","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.ekir.2017.07.002","article-title":"Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy","volume":"2","author":"Yamada","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jaut.2022.102883_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000505748","article-title":"LIF signaling enhances production of galactose-deficient IgA1 in IgA nephropathy","volume":"6","author":"Yamada","year":"2020","journal-title":"Kidney Dis."},{"key":"10.1016\/j.jaut.2022.102883_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ndt\/gfaa356","article-title":"Relationship between immunoglobulin A1 lectin-binding specificities, mesangial C4d deposits and clinical phenotypes in immunoglobulin A nephropathy","volume":"37","author":"Medrano","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jaut.2022.102883_bib23","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.molimm.2006.12.011","article-title":"Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins","volume":"44","author":"Moore","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jaut.2022.102883_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2144\/btn-2018-0042","article-title":"Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients","volume":"65","author":"Reily","year":"2018","journal-title":"Biotechniques"},{"key":"10.1016\/j.jaut.2022.102883_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2144\/btn-2020-0044","article-title":"Assigning immunoglobulin class from single-cell transcriptomes in IgA1-secreting versus membrane subpopulations","volume":"70","author":"Reily","year":"2021","journal-title":"Biotechniques"},{"key":"10.1016\/j.jaut.2022.102883_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1681\/ASN.2020060823","article-title":"Interaction between G ALNT12 and C1GALT1 associates with galactose-deficient IgA1 and IgA nephropathy","volume":"32","author":"Wang","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2022.102883_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/ki.2011.16","article-title":"Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Sch\u0151nlein purpura nephritis","volume":"80","author":"Kiryluk","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2022.102883_bib28","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jaut.2022.102883_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ki.1984.213","article-title":"Circulating and mesangial secretory component-binding IgA-1 in primary IgA nephropathy","volume":"26","author":"Valentijn","year":"1984","journal-title":"Kidney Int."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122000919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122000919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:30:14Z","timestamp":1760257814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841122000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":29,"alternative-id":["S0896841122000919"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102883","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphatase control of cytokine-mediated overproduction of galactose-deficient IgA1, the main autoantigen in IgA nephropathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102883"}}